Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
38 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1 Ahmad Hussein Awada
  • ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Lung phase 3 Closed 4 lines chemotherapy and radiation Bogdan Grigoriu
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1 Philippe Aftimos
  • AMG510 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Multiple phase 1/2 Open Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation Nuria Kotecki
  • ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) NSCLC phase 3 Open Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior Thierry Berghmans
  • Apple APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients Lung phase 3 Closed EGFR activating mutation associated with EGFR-TKI sensitivity Thierry Berghmans
  • ARTEMIDE-01 A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001) Lung phase 1/2 Open Mariana Brandao
  • B079201215796 Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party Lung phase 2 Open Nodule 5-20 mm of undetermined nature in at least one lung. Thierry Berghmans
  • B079201523324 Does inflammation have a significant implication in Lung Cancer evolution? Lung Closed Lung cancerNo prior treatment Anne-Pascale Meert
  • BLU-667-2303 A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer Lung phase 3 Open RET-fusion Thierry Berghmans
  • CANFOUR An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Multiple phase 1/2 Open Metastatic Christiane Jungels
  • CANOPY-N A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) Lung phase 2 Open Bogdan Grigoriu
  • CLDK378A2303 A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib Multiple phase 3 Closed Anaplasic lymphoma kinase (ALK) positive Thierry Berghmans
  • D5164C00001 ADAURA A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) NSCLC phase 3 Closed EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. Thierry Berghmans